Diving deep into the hemophilia market, Sanofi strikes an $11.6B Bioverativ buyout
Sanofi $SNY has finally bagged a multibillion-dollar biotech buyout.
In a statement early Monday the pharma giant said it has closed a deal to acquire Biogen spinout Bioverativ $BIVV for almost $11.6 billion — a 64% premium on its $64.11 Friday close at $105 a share. The acquisition helps explain a newly reworked pact with Alnylam that put Sanofi on course to building a franchise in the hemophilia field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.